论文部分内容阅读
目的:进一步研究新型佐剂CTA1-DD/IgG的免疫调节作用。方法:小鼠经鼻内免疫抗原(鸡卵清白蛋白OVA)联合佐剂CTA1-DD或CTA1-DD/IgG复合物,用ELISA检测血清中OVA特异性IgG抗体生成和IgG抗体亚类,用酶联免疫斑点试验检测脾脏抗体分泌细胞。结果:CTA1-DD/IgG佐剂在小鼠中诱导血清特异性IgG抗体及脾脏特异性抗体分泌细胞的能力均高于CTA1-DD佐剂;CTA1-DD/IgG或CTA1-DD作为佐剂联合OVA免疫后IgG1、IgG2a、IgG2b抗体皆提高,且IgG2a/IgG1>1。结论:CTA1-DD/IgG佐剂的免疫调节作用强于CTA1-DD,且能产生混合IgG抗体亚型,促进平衡的免疫应答。
Objective: To further study the immunomodulatory effect of a novel adjuvant CTA1-DD / IgG. Methods: Mice were immunized with intranasal immunization antigen (chicken egg albumin OVA) and adjuvant CTA1-DD or CTA1-DD / IgG complex. Serum OVA-specific IgG antibody and IgG antibody subtype were detected by ELISA. Detection of splenic antibody-secreting cells by co-immunoblot assay. Results: The ability of CTA1-DD / IgG adjuvant to induce serum-specific IgG and spleen-specific antibody-secreting cells in mice was higher than that of CTA1-DD adjuvant. CTA1-DD / IgG or CTA1-DD was adjuvant After OVA immunization IgG1, IgG2a, IgG2b antibodies were increased, and IgG2a / IgG1> 1. Conclusion: The immunomodulatory effect of CTA1-DD / IgG adjuvant is stronger than that of CTA1-DD, and can produce mixed IgG antibody subtype and promote balanced immune response.